Thursday, October 28

Spain, with the horizon of having seven vaccines

Pfizer building in Madrid.

Pfizer building in Madrid.

Spain has on the horizon to acquire seven different types of COVID vaccines, and some are beginning to be a reality since they expect to receive in December just over three million doses of Astrazeneca and from the beginning of the year to have 20 million of Pfizer.

From the Ministry of Health, both the Minister Salvador Illa and the Secretary of State Silvia Calzón, have referred in some of their interventions to a horizon of seven types of vaccines, of seven different pharmaceutical companies, to stop the coronavirus, whose deadlines will be determined by the clinical development of the drug and the authorizations, always with the maximum guarantees of safety.

Specifically, Calzón said in his parliamentary appearance to expose the budgets of his Ministry – in which 1,000 million euros are collected for vaccines – that Spain is preparing for a purchase of vaccines against the coronavirus that “will exceed the number of Spaniards” .

It was yesterday when the American pharmacist Pfizer and Germany’s BioNTech reported that their vaccine studies show greater than 90% efficacy in participants with no previous evidence of infection. Efficacy has been verified seven days after the second dose and a total of 28 days after the start of vaccination.

Pfizer said in its announcement statement that based on its projections, it expects to globally produce up to 50 million doses of the vaccine in 2020 and up to 1.3 billion doses in 2021.

Illa has considered that the ad is “a promising and relevant step” and has calculated that Spain will have 20 million doses that would immunize 10 million people from the beginning of 2021 or if “everything went very well” by the end of 2020.

For the vice president of the Spanish Association of Vaccination (AEV), Fernando Moraga-Llop, the efficacy of this vaccine is “great news” because, for example, that of the flu “many times” is between 50 and 60% and it is given as “very good”.

However, he points out in statements to Efe that it must be taken with “caution” and remember that this vaccine has to be kept at a temperature of about -70 degrees, which is “a solvable problem but it must be taken into account for logistical issues.” “I don’t know if all the vaccination centers will be in storage and distribution conditions,” Moraga-Llop points out.

Apart from that of Pfizer, the Council of Ministers authorized the advance purchase of vaccines on October 20, which will facilitate that Spain receives 31,555,469 million doses of the drug from Astrazeneca, of which 3.1 million will arrive in December If it passes all the security filters, as the minister advanced then.

300 million doses for Europe

In this way, Spain will specify the terms of the formal purchase agreement, signed on August 27, between the European Commission, on behalf of the member countries, and the pharmaceutical company. The agreement established the acquisition for Europe of 300 million doses for a total cost of 870 million euros.

The signing of advanced purchase agreements, Health then explained, aims for the EU to adopt the necessary measures to guarantee a safe and effective vaccine to the Member States and that negotiations with pharmaceutical companies “be done under the best possible conditions. “.

Population criteria are taken into account to calculate the doses assigned to each of the Member States.

The european commission also has already signed contracts with Janssen, belonging to the US group Johnson & Johnson, and with Sanofi-GSK.

Health trusts that a “relevant population” in Spain will be vaccinated at the beginning of May and everything indicates that there is consensus as to who will be the first groups to receive the drug.

Last September Health and communities agreed to implement a common vaccination strategy, which will be prepared jointly, taking into account the opinion of experts in bioethics and scientific societies and will be approved in the Plenary of the Interterritorial Council of the National Health System.

One of the companies consulted is the AEV and its vice president confirms that consensus to be those over 65 years of age, and those who have diseases that predispose serious forms of COVID-19, people who are in geriatric residences, as well as health personnel and other essential services professionals are the first to be vaccinated.

Leave a Reply

Your email address will not be published. Required fields are marked *